Quest for the right Drug
לורמיקס 200 מ"ג LORMYX 200 MG (RIFAXIMINE)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
פומי : PER OS
צורת מינון:
טבליות מצופות פילם : FILM COATED TABLETS
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
4.8 Undesirable effects Clinical Trials During double-blind controlled clinical trials or clinical pharmacology studies, LORMYX 200 mg effects have been compared to placebo and other antibiotics, therefore quantitative safety data are available. Note: The majority of adverse reactions listed (in particular for gastrointestinal disorders) may also be attributable to the underlying diseases being treated and have been reported during clinical trials at the same frequency as the one reported in placebo-treated patients. Post-marketing experience During post-approval use of LORMYX 200 mg further undesirable effects have been reported, whose frequency is not known. Frequency categories are defined using the following convention: Very common (≥1/10); Common (≥1/100 to <1/10); Uncommon (≥1/1,000 to <1/100); Rare (≥1/10,000 to <1/1,000); Very rare (<1/10,000), Not known (frequency cannot be estimated from the available data). Frequency of undesirable effects MedDRA System Common Uncommon Unknown Organ Class Infections and Candidiasis, Clostridial infection infestations Herpes simplex, Nasopharyngitis, Pharyngitis, Upper respiratory tract infection Blood and Lymphocytosis, Thrombocytopenia lymphatic system Monocytosis, disorder Neutropenia Immune Anaphylactic reaction, system Hypersensitivity disorders Metabolism and Decreased appetite, nutrition Dehydration disorders Psychiatric disorders Abnormal dreams, Depressed mood, Insomnia, Nervousness Nervous Dizziness, Hypoesthesia, Presyncope system Headache Migraine, disorders Paraesthesia, Sinus headache, Somnolence Eye disorders Diplopia Ear and labyrinth Ear pain, disorders Vertigo Cardiac disorders Palpitations Vascular disorders Blood pressure increased, Hot flush Respiratory, Cough, thoracic, and Dry throat, mediastinal Dyspnoea, disorders Nasal congestion, Oropharyngeal pain, Rhinorrhea Gastrointestinal Abdominal pain, Abdominal pain upper, disorders Constipation, Ascites, Defecation Dry lip, urgency, Dyspepsia, Diarrhoea, Gastrointestinal motility Flatulence, disorder, Abdominal Faeces hard, distension, Haematochezia, Nausea, Mucous stools, Vomiting, Taste disorders Rectal tenesmus Hepatobiliary disorders Aspartate Liver function tests aminotransferase abnormalities increased Skin and Rashes, Stevens-Johnson syndrome* subcutaneous tissue Eruptions and Toxic Epidermal Necrolysis* disorders exanthemas, Angioedema, (partially as signs of Sunburn 1 Dermatitis, hypersensitivity Dermatitis exfoliative, reactions) Eczema, Erythemas, Pruritus, Musculoskeletal Back pain, Muscle and Connective spasms, Muscular tissue disorders weakness, Myalgia, Neck pain Renal and urinary Blood in urine, disorders Glycosuria, Pollakiuria, Polyuria, Proteinuria Reproductive Polymenorrhoea system and breast disorders General disorders Pyrexia Asthenic conditions, and administration Chills, site conditions Cold sweat, Hyperhidrosis, Influenza like illness, Oedema peripheral, Pain and discomfort Investigations International normalised ratio abnormal *Severe Cutaneous Adverse Reactions have been observed in patients with cirrhosis. 1 As the investigator reported “sunburn” this is not be considered as generally referring to photosensitivity but actually to “sunburn” Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form https://sideeffects.health.gov.il
פרטי מסגרת הכללה בסל
התרופה תינתן לטיפול באנצפלופתיה כבדית בחולה שלא מגיב או שאינו סובל את הטיפול ב-LACTULOSE.
מסגרת הכללה בסל
התוויות הכלולות במסגרת הסל
התוויה | תאריך הכללה | תחום קליני | Class Effect | מצב מחלה |
---|---|---|---|---|
התרופה תינתן לטיפול באנצפלופתיה כבדית בחולה שלא מגיב או שאינו סובל את הטיפול ב-LACTULOSE. |
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
09/01/2013
הגבלות
תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת
מידע נוסף